Wall Street analyst estimates for Adial Pharmaceuticals, Inc. (ADIL): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-0.17 | ||
| 2026-08-12 | $-11.25 | $-1.03 | -992.2% |
| 2026-05-13 | $-1.48 | $-2.73 | +45.8% |
| 2026-03-10 | $-1.81 | $-2.10 | +13.8% |
| 2025-11-13 | $-2.00 | $-2.25 | +11.1% |
| 2025-08-13 | $-4.50 | $-5.50 | +18.2% |
| 2025-05-14 | $-8.50 | $-12.50 | +32.0% |
| 2025-03-04 | $-3.75 | $-9.50 | +60.5% |
Valuation Ratios
| Price / Book | 155.24 |
| EV / EBITDA | 0.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $565 | $565 | $563 | $565 | $564 | 0 | 0 | $564 | 0 | 0 |
| Gross Profit | -$565 | -$565 | -$563 | -$565 | -$564 | 0 | 0 | -$564 | 0 | 0 |
| Research & Development | $146143 | $182107 | $368459 | $4.0M | $5.9M | $8.4M | $2.0M | $1.3M | $3.2M | $2.6M |
| Selling, General & Admin | $264664 | $813179 | $6.6M | $4.3M | $5.1M | $9.3M | $8.9M | $5.6M | $5.1M | $5.2M |
| Operating Expenses | $410807 | $995286 | $7.0M | $8.2M | $10.9M | $19.3M | $10.9M | $6.9M | $8.3M | $7.8M |
| Operating Income | -$410807 | -$995286 | -$7.0M | -$8.2M | -$10.9M | -$19.3M | -$10.9M | -$6.9M | -$8.3M | -$7.8M |
| EBITDA | -$410002 | -$994354 | -$7.0M | -$8.6M | -$10.9M | -$17.7M | -$10.8M | -$7.0M | -$13.2M | -$8.0M |
| Interest Expense | $9643 | $144537 | $1.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$420200 | -$1.1M | -$11.6M | -$8.6M | -$10.9M | -$19.5M | -$10.8M | -$7.0M | -$13.2M | -$8.0M |
| Income Tax | 0 | $367 | 0 | 0 | -$32495 | -$94077 | 0 | 0 | 0 | 0 |
| Net Income | -$420200 | -$1.1M | -$11.6M | -$8.6M | -$10.9M | -$19.4M | -$12.7M | -$7.0M | -$13.2M | -$8.0M |
| EPS | $-55.00 | $-130.00 | $-1527.50 | $-545.00 | $-544.75 | $-653.00 | $-299.50 | $-136.00 | $-17.75 | $-11.93 |
| EPS (Diluted) | $-55.00 | $-130.00 | $-1527.50 | $-545.00 | $-544.75 | $-653.00 | $-299.50 | $-136.00 | $-17.75 | $-11.93 |
| Shares Outstanding (Diluted) | $7645 | $8760 | $7615 | $15764 | $19941 | $29742 | $42521 | $56986 | $743550 | $668630 |
Price
| Price | $5.24 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · APRE · BCDA · BCLI · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ADIL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks